PortfoliosLab logoPortfoliosLab logo
GNOM vs. GERM
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

GNOM vs. GERM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Global X Genomics & Biotechnology ETF (GNOM) and Amplify Treatments, Testing and Advancements ETF (GERM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


GNOM

1D
1.99%
1M
5.82%
YTD
7.81%
6M
6.65%
1Y
54.21%
3Y*
-0.94%
5Y*
-10.20%
10Y*

GERM

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
0.00%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

GNOM vs. GERM - Yearly Performance Comparison


2026 (YTD)20252024
GNOM
Global X Genomics & Biotechnology ETF
7.81%18.65%-9.08%
GERM
Amplify Treatments, Testing and Advancements ETF
0.00%0.00%0.00%

GNOM vs. GERM - Sectors Allocation Comparison


Sectors
GNOM
GERM

Healthcare

99.6%
99.3%

Technology

0.4%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

0.4%

Industrials

-

-

Real Estate

-

-

Utilities

-

-

Healthcare

GNOM
99.6%
GERM
99.3%

Technology

GNOM
0.4%
GERM

-

Basic Materials

GNOM

-

GERM

-

Communication Services

GNOM

-

GERM

-

Consumer Cyclical

GNOM

-

GERM

-

Consumer Defensive

GNOM

-

GERM

-

Energy

GNOM

-

GERM

-

Financial Services

GNOM

-

GERM
0.4%

Industrials

GNOM

-

GERM

-

Real Estate

GNOM

-

GERM

-

Utilities

GNOM

-

GERM

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GNOM vs. GERM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOM
GNOM Risk / Return Rank: 5757
Overall Rank
GNOM Sharpe Ratio Rank: 6060
Sharpe Ratio Rank
GNOM Sortino Ratio Rank: 6161
Sortino Ratio Rank
GNOM Omega Ratio Rank: 5353
Omega Ratio Rank
GNOM Calmar Ratio Rank: 6060
Calmar Ratio Rank
GNOM Martin Ratio Rank: 5151
Martin Ratio Rank

GERM
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNOM vs. GERM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and Amplify Treatments, Testing and Advancements ETF (GERM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GNOMGERMDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.33

Calmar ratioReturn relative to maximum drawdown

3.00

Martin ratioReturn relative to average drawdown

8.62

GNOM vs. GERM - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


GNOMGERMDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.06

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.09

Drawdowns

GNOM vs. GERM - Drawdown Comparison

The maximum GNOM drawdown since its inception was -75.00%, which is greater than GERM's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for GNOM and GERM.


Loading charts...

Drawdown Indicators


GNOMGERMDifference

Max Drawdown

Largest peak-to-trough decline

-75.00%

0.00%

-75.00%

Max Drawdown (1Y)

Largest decline over 1 year

-18.17%

0.00%

-18.17%

Max Drawdown (3Y)

Largest decline over 3 years

-46.47%

Max Drawdown (5Y)

Largest decline over 5 years

-72.29%

Current Drawdown

Current decline from peak

-55.45%

0.00%

-55.45%

Average Drawdown

Average peak-to-trough decline

-40.55%

0.00%

-40.55%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.30%

0.00%

+6.30%

Volatility

GNOM vs. GERM - Volatility Comparison

Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 8.47% compared to Amplify Treatments, Testing and Advancements ETF (GERM) at 0.00%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than GERM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GNOMGERMDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.47%

0.00%

+8.47%

Volatility (6M)

Calculated over the trailing 6-month period

19.44%

0.00%

+19.44%

Volatility (1Y)

Calculated over the trailing 1-year period

26.50%

0.00%

+26.50%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

33.57%

0.00%

+33.57%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

34.17%

0.00%

+34.17%

GNOM vs. GERM - Expense Ratio Comparison

GNOM has a 0.50% expense ratio, which is lower than GERM's 0.68% expense ratio.


Dividends

GNOM vs. GERM - Dividend Comparison

GNOM's dividend yield for the trailing twelve months is around 1.27%, while GERM has not paid dividends to shareholders.


PositionTTM202520242023202220212020
GERM
Amplify Treatments, Testing and Advancements ETF
0.00%0.00%0.00%0.00%0.00%0.00%0.00%
GNOM
Global X Genomics & Biotechnology ETF
1.27%1.37%0.00%0.00%0.00%0.03%0.14%

Frequently Asked Questions


GNOM has higher volatility (8.47%) compared to GERM (0.00%). In terms of maximum drawdown, GNOM dropped -75.00% vs GERM's 0.00%.

On 1-year performance, GNOM leads with 54.21% vs 0.00% for GERM. On fees, GNOM is cheaper at 0.50% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 1-year period, GNOM has performed better with a 54.21% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

GNOM is cheaper with a 0.50% expense ratio, compared with 0.68% for GERM.

GNOM has the higher dividend yield at 1.27%, compared with 0.00% for GERM.

GNOM tracks Solactive Genomics Index, while GERM tracks Prime Treatments, Testing and Advancements Index. They also come from different issuers: Global X and Amplify. Their fees differ too: 0.50% for GNOM and 0.68% for GERM.

Portfolio Optimizer

Find the right allocation for GNOM and GERM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer